The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase III trial evaluating glofitamab in combination with gemcitabine plus oxaliplatin versus rituximab in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
 
Mark Hertzberg
Honoraria - BMS; Janssen; Roche/Genentech; Takeda
Consulting or Advisory Role - Janssen; MSD; Roche; Takeda
Travel, Accommodations, Expenses - Takeda
 
Matthew Ku
Consulting or Advisory Role - Antengene; Roche
Research Funding - Karyopharm Therapeutics
 
Olivier Catalani
Employment - Roche
 
Betsy Althaus
Employment - Genentech
Stock and Other Ownership Interests - Roche
 
Stephen Simko
Employment - Genentech
Stock and Other Ownership Interests - Roche
 
Gareth P. Gregory
Honoraria - Roche
Consulting or Advisory Role - Gilead Sciences; Janssen; Roche; Sandoz-Novartis
Speakers' Bureau - Roche
Research Funding - Abbvie (Inst); BeiGene (Inst); Janssen (Inst); MSD (Inst); Roche (Inst)
Expert Testimony - Janssen
Travel, Accommodations, Expenses - Novartis; Roche